Purpose: To determine the biodistribution of Tc-99m labeled somatostatin receptor-binding peptide (Depreotide) on planar and SPECT studies of the thorax and upper abdomen in order to improve diagnostic accuracy.
Methods And Materials: Retrospectively 29 planar and SPECT studies from 28 patients (all males, average age of 65.79) were reviewed. All the patients had been referred for evaluation of solitary pulmonary nodules. Two to four hours after IV injection of 555- to 740-MBq (15-20 mCi) Tc-99m Depreotide, anterior and posterior total body images, and anterior, posterior, right lateral and left lateral planar images were obtained, and thoracic SPECT was acquired with a three-head gamma camera. The degree of uptake in the lungs, thoracic cage, and organs of the upper abdomen was rated from "0" to "++++".
Results: The range of normal activity in the thorax includes cardiac, "0"; pulmonary, "+"; rib, "+/++"; sternum, "++"; vertebrae, "++". The degree of normal activity seen in the upper abdominal organs includes liver and spleen, "+++", and kidneys, "+++/++++". Eight patients with emphysema had diffuse pulmonary uptake graded as "+/++". One patient with left pneumonectomy and radiation therapy to the left hemithorax had photon-deficiency in the left hemithorax and decreased to absent uptake including the vertebrae and ribs. Although some cases had background pulmonary uptake of Tc-99m Depreotide, the bone/ bone marrow activity of the thoracic cage including the ribs, sternum, and thoracic spine is sufficiently great enough to produce a clear distinction between bone and lung in the thoracic cavity that gives high-contrast resolution on SPECT.
Conclusions: The intensity of radioactivity in the sub-diaphragmatic organs such as the liver, spleen, and kidneys provides useful guidance for the categorization of pulmonary lesions. The uptake of land marks such as the sternum, which is anteriorly located, and the thoracic vertebrae, which are posteriorly located in the thoracic cage, can be used in the localization of a Depreotide avid tumor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF02996303 | DOI Listing |
Clin Nucl Med
January 2025
From the Department of Radiology.
Purpose: To evaluate the predictive ability of 99mTc-galactosyl human serum albumin SPECT/CT quantitative parameters for posthepatectomy liver failure (PHLF).
Methods: Sixty-eight patients who underwent 99mTc-galactosyl human serum albumin scintigraphy as a preoperative examination for hepatectomy between July 2021 and December 2023 were prospectively evaluated. The patients were divided into PHLF and non-PHLF groups.
Curr Cardiol Rep
January 2025
Department of Cardiac Sciences, University of Calgary and Libin Cardiovascular Institute, Calgary, AB, Canada.
Purpose Of Review: This review evaluates recent advancements in Technetium-99 m pyrophosphate (99mTc-PYP) imaging for transthyretin amyloid cardiomyopathy (ATTR-CM). We summarize the advantages of single-photon emission computed tomography (SPECT) over planar imaging, the potential impact of quantitative methods, and emerging data for quantifying response to therapy.
Recent Findings: The current literature demonstrates the superior diagnostic accuracy of SPECT compared with planar imaging in 99mTc-PYP studies.
Front Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2025
Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Objective: Tafamidis has shown potential in slowing disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate serial changes on [Tc]Tc-pyrophosphate (PYP) scintigraphy during tafamidis treatment for hereditary ATTR-CM.
Methods: We retrospectively analyzed a prospectively collected cohort of Ala97Ser (A97S) hereditary ATTR-CM patients treated with tafamidis (61 mg/day) and a control group comprising A97S hereditary ATTR-CM patients who had not received disease-modifying medications.
Data Brief
February 2025
Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud, San Lorenzo 111421, Paraguay.
This article presents 582 bone scan images from 291 adult patients who attended the Nuclear Medicine Service at the Instituto de Investigaciones en Ciencias de la Salud (IICS) of the Universidad Nacional de Asunción (UNA), Paraguay, between 2020 and 2024. The images were acquired using trimodal SPECT-CT-PET equipment, model AnyScan SCP, and the MEDISO brand. Approximately 20 mCi of technetium-99m methylene diphosphonate (Tc-MDP) was administered to each patient, producing whole-body planar images in anterior and posterior projections of the axial and appendicular skeleton with a resolution of 256 × 1024 pixels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!